How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

29,491 results for

Intravenous Drug Abuse

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Management options in the treatment of femoral pseudoaneurysms secondary to intravenous drug abuse: A case series Full Text available with Trip Pro

Management options in the treatment of femoral pseudoaneurysms secondary to intravenous drug abuse: A case series Infected femoral pseudoaneurysms are a common presentation in intravenous drug users with little consensus as to the optimum management of these patients. Whilst emergency revascularisation options are available, excision and ligation of the femoral artery remains the most common operative intervention but risks leaving the patient with critical ischaemia or intermittent

2017 International journal of surgery case reports

22. An Invasive Case of Left-Sided Endocarditis Caused by Pseudomonas aeruginosa in a Patient with History of Intravenous Drug Abuse Full Text available with Trip Pro

An Invasive Case of Left-Sided Endocarditis Caused by Pseudomonas aeruginosa in a Patient with History of Intravenous Drug Abuse Infective endocarditis, caused by Pseudomonas aeruginosa, is rarely seen in clinical practice. It has been reported mainly in intravenous drug abusers (IVDA). We present a case of a 63-year-old male who presented with abdominal pain and fever. Computed tomography (CT) abdomen showed splenic and renal infarct. The blood culture grew Pseudomonas aeruginosa

2017 Cureus

23. Cardiac Arrest Following Drug Abuse with Intravenous Tapentadol: Case Report and Literature Review Full Text available with Trip Pro

Cardiac Arrest Following Drug Abuse with Intravenous Tapentadol: Case Report and Literature Review BACKGROUND Tapentadol is a centrally acting opioid analgesic, with a dual mode of action, as a norepinephrine reuptake inhibitor and an agonist of the μ-opioid receptor (MOR). Tapentadol is used for the management of musculoskeletal pain, and neuropathic pain associated with diabetic peripheral neuropathy. CASE REPORT A 32-year-old woman attended hospital for evaluation of an intractable headache (...) . Computed tomography and magnetic resonance imaging of the brain were negative. She was found unresponsive in the bathroom on the day following hospital admission, and despite resuscitative measures, the patient died following cardiac arrest. Autopsy toxicology revealed significantly elevated levels of tapentadol, and bedside evidence suggested that the patient had self-administered this medication intravenously before her death. CONCLUSIONS We report a rare adverse effect of tapentadol causing

2017 The American journal of case reports

24. Iris abscess a rare presentation of intravenous drug abuse associated Candida endophthalmitis Full Text available with Trip Pro

albicans, and she received voriconazole. This led to resolution of the condition with a final visual acuity of 20/20 at six month follow up.An iris abscess is a rare clinical presentation of intravenous drug use-associated endogenous endophthalmitis and as a result may present a diagnostic challenge as it requires a high level of clinical suspicion and a detailed social history to elicit the drug abuse. Early diagnosis and aggressive therapy is the key to better visual outcomes in these patients. (...) Iris abscess a rare presentation of intravenous drug abuse associated Candida endophthalmitis To describe an unusual case of intravenous drug abuse associated endogenous endophthalmitis presenting with an iris abscess.A 30-year old female with history of intravenous drug use presented with a two-week history of redness and blurry vision in the right eye. An initial diagnosis of anterior uveitis was made. However, she worsened on topical steroids and mydriatics. She was found to have a hypopyon

2016 American journal of ophthalmology case reports

25. Intravenous Drug Abuse

Abuse Aka: Intravenous Drug Abuse , Persons Who Inject Drugs , Intravenous Drug User , Injection Drug Abuse , IV Drug Abuse , IVDA , PWID From Related Chapters II. Epidemiology : 750,000 current injection drug users in U.S. (2014) Adults in U.S. who have used IV Drugs: 2% (or 6.5 Million) Mortality while actively injecting drugs: 2.6 per 100 person years III. Causes Most commonly abused IV drugs Other s abused via injection IV. Exam See See Observe for injection sites Localized or pigmentation (...) Intravenous Drug Abuse Intravenous Drug Abuse Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Intravenous Drug Abuse Intravenous Drug

2019 FP Notebook

26. An Outbreak of Endogenous Fungal Endophthalmitis Among Intravenous Drug Abusers in New England. Full Text available with Trip Pro

An Outbreak of Endogenous Fungal Endophthalmitis Among Intravenous Drug Abusers in New England. Intravenous drug abuse (IVDA) is a known risk factor for endogenous fungal endophthalmitis (EFE), a severe intraocular infection caused by hematogenous seeding of mycotic organisms to the eye. Reporting significant increases in heroin-related deaths since 2014, the New England region is in the midst of an opioid crisis that has led to a substantial increase in patients at risk for this vision (...) -threatening disease.To present an update on characteristics, management, and visual outcomes in patients with EFE.Medical records review was initiated on July 1, 2016, evaluating all patients with EFE referred to New England Eye Center at Tufts Medical Center, a tertiary care ophthalmology practice distributed throughout Massachusetts, from May 1, 2014, to May 1, 2016. Patients with a history of IVDA and culture-proven or clinical evidence of fungal endophthalmitis were included.Intravenous drug

2017 JAMA ophthalmology

27. Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers. (Abstract)

Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers. Staphylococcus aureus is the commonest cause of acute endocarditis in intravenous drug abusers. In-vitro and in-vivo animal studies have found increased killing of organisms with the combination of a beta-lactam antibiotic and an aminoglycoside. These findings have created a controversy about the use of such combination therapy. We randomly treated 25 episodes of S. aureus endocarditis in intravenous drug (...) abusers with either single or combination antibiotic regimens. Mean days to defervescence were similar in both groups: 6.3 d (SEM, 1.49 d) for the single drug group and 6.6 d (SEM, 1.02 d) for the group treated in combination with an aminoglycoside. There were no bacteriologic failures or relapses in either group. No patients needed valvular surgery, and the mortality rate was zero. Thus, it appears that single drug therapy with an appropriate beta-lactam antibiotic is adequate and appropriate

1979 Annals of internal medicine Controlled trial quality: uncertain

28. Health Care Utilization and Payments of Postoperative and Drug Abuse-Related Spinal Infections. (Abstract)

days, p < 0.0001). Exposure to IV drug abuse was associated with increased risk of complications compared to the control group (43% vs 38%, p < 0.0001). Payments at one-month follow-up were significantly (p < 0.0001) higher among the postsurgical group compared to both groups. However, at 12-months follow-up, payments were significantly (p < 0.0001) higher in the drug abuse group compared to both groups. Only postsurgical infections were associated with higher number of surgical interventions both (...) at presentation and 1 year follow up.SI following surgery or IV drug abuse are associated with higher payments, complication rates, and longer hospital stays. Drug abuse related SI are associated with the highest complication rates, readmissions and overall payments at one year of follow up despite the lower rate of surgical interventions.3.

2019 Spine

29. A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure Which Aims to Evaluate Whether GRT0151Y is Likely to be Abused

A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure Which Aims to Evaluate Whether GRT0151Y is Likely to be Abused A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure Which Aims to Evaluate Whether GRT0151Y is Likely to be Abused - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning (...) You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure Which Aims to Evaluate Whether GRT0151Y is Likely to be Abused The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier

2018 Clinical Trials

30. Child Abuse, Elder Abuse, and Intimate Partner Violence

64 a. Acute Traumatic, Medical, and Psychological Care 64 b. Trauma-Informed Care 65 c. Teamwork 66 2 d. Ensuring Patient Safety 68 e. Reporting Elder Abuse 69 Best Practices Guidelines for Trauma Center Recognition: Intimate Partner Violence 71 1. Overview 72 2. Assessment 74 a. Screening 74 3. Intervention 78 a. Medical and Psychosocial Interventions 78 b. Addressing Patient Safety 79 c. Teamwork 82 d. Reporting to Law Enforcement 84 Best Practices Guidelines for Trauma Center Recognition: Sex (...) % of sentinel injuries were recognized by medical providers in a hospital-based setting. 8 Medical providers must maintain a high index of suspicion throughout the continuum of trauma care to identify sentinel injuries. An estimated 1,720 children died from maltreatment in 2017 , an 1 1% increase from the 2013 5 . Children younger than 3 years accounted for more than 70% of all fatalities. Of the children who died, 41.6% suffered physical child abuse (PCA) exclusively or in combination with another

2019 American College of Surgeons

31. Effect of Developmentally Adapted Cognitive Processing Therapy for Youth With Symptoms of Posttraumatic Stress Disorder After Childhood Sexual and Physical Abuse: A Randomized Clinical Trial. (Abstract)

Effect of Developmentally Adapted Cognitive Processing Therapy for Youth With Symptoms of Posttraumatic Stress Disorder After Childhood Sexual and Physical Abuse: A Randomized Clinical Trial. Despite the high prevalence, evidence-based treatments for abuse-related posttraumatic stress disorder (PTSD) in adolescents have rarely been studied.To examine whether developmentally adapted cognitive processing therapy (D-CPT) is more effective than a wait-list condition with treatment advice (WL/TA (...) ) among adolescents with PTSD related to childhood abuse.This rater-blinded, multicenter, randomized clinical trial (stratified by center) enrolled treatment-seeking adolescents and young adults (aged 14-21 years) with childhood abuse-related PTSD at 3 university outpatient clinics in Germany from July 2013 to June 2015, with the last follow-up interview conducted by May 2016. Of 194 patients, 88 were eligible for randomization.Participants received D-CPT or WL/TA. Cognitive processing therapy

2019 JAMA psychiatry (Chicago, Ill.) Controlled trial quality: predicted high

32. Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy)

. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy) Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy) July 2017 Nivolumab is a drug which blocks a protein, called the programmed death-1 (PD-1) receptor, on the surface of certain immune cells (...) including Screening Immunology and Allergy Infectious Disease and Immunisation Mens Health and Sexual Health Mental Health Drug Abuse and Learning Difficulties Musculoskeletal Neurology and Neurosurgery Other Paediatrics and Neonatology Pregnancy and Childbirth Radiology Imaging and Nuclear Medicine Rehabilitation and Disability Renal Disease and Urology Respiratory Disease and Thoracic Surgery Skin Disease Burns and Wound Care Check All By clicking "subscribe" I confirm that I am happy to receive

2017 NIHR Innovation Observatory

33. Intrapartum care for women with existing medical conditions or obstetric complications and their babies

with mechanical heart valves. 1.3.17 Consider planned caesarean section for women with: any disease of the aorta assessed as high risk Intrapartum care for women with existing medical conditions or obstetric complications and their babies (NG121) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated April 2019 Page 12 of 96pulmonary arterial hypertension NYHA class III or IV heart disease. Explain the benefits and risks (...) for women with existing medical conditions or obstetric complications and their babies (NG121) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated April 2019 Page 13 of 96NYHA class IV heart disease. 1.3.21 For women with heart disease in whom fluid balance is critical for optimal cardiac function, offer tailored monitoring and clinical review during the intrapartum period, and consider escalation as follows: hourly

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

34. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies. Full Text available with Trip Pro

Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies. Providers who treat patients with chronic pain face a dual challenge: providing adequate access to opioid therapies for appropriate pain management while adopting strategies to minimize the risk for abuse. Commonly prescribed opioids have substantial abuse potential when administered intravenously, and extended-release (ER)/long-acting (LA) opioids may be targeted for IV abuse (...) because of the higher per-dose medication level. The consequences of IV opioid abuse are severe and increase the risks for adverse outcomes, including mortality due to acute health events, serious infections, and deep vein thrombosis, to name a few. To reduce the potential for abuse of prescription opioids by both recreational and experienced drug abusers, abuse-deterrent formulations (ADFs) of opioid medications employ either physical/chemical barriers or agonist-antagonist combinations. Here we

2018 Pain Practice

35. What is the current evidence for the efficacy of drug consumption rooms?

Supervised Injection Site in the U.S. American Journal of Preventive Medicine. 2017;53(6):919-22. 28. Fast D, Small W, Wood E, Kerr T. The perspectives of injection drug users regarding safer injecting education delivered through a supervised injecting facility. Harm Reduction Journal. 2008;5:32. 29. Wood E, Tyndall MW, Montaner JS, Kerr T. Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. CMAJ. 2006;175(11):1399-404. 30. Hunt N, Lloyd C, Kimber J, Tompkins (...) injection services and police: A qualitative interview study of international stakeholders. International Journal of Drug Policy. 2018;61:1-6. 49. DeBeck K, Wood E, Zhang R, Tyndall M, Montaner J, Kerr T. Police and public health partnerships: evidence from the evaluation of Vancouver's supervised injection facility. Substance abuse treatment, prevention, and policy. 2008;3:11. 50. Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection facility. Canadian Medical Association

2020 Public Health England - Evidence Briefings

36. Possible benefits of providing safe supply of substances to people who use drugs during public health emergencies such as the COVID-19 pandemic

The North American Opiate Medication Initiative (NAOMI) trial, conducted in Vancouver from 2005 to 2008, compared injectable diacetylmorphine (pharmaceutical heroin) with oral methadone maintenance therapy in patients with opioid dependence that did not respond to treatment (11). This study found that injectable diacetylmorphine was more effective in retaining participants and reducing rates of illicit drug use or other illegal activity (11). The NAOMI trial was later followed by the Study to Assess (...) involved fentanyl or fentanyl analogues (1), a powerful opioid that can cause overdose and death, even when used in small amounts (14). The growing number of overdose deaths has increased concerns about people buying street drugs not knowing what is in them. Safe supply is defined as “an approach that focuses on saving lives by using existing pharmaceutical-grade medications as an alternative to highly toxic street drugs for people at risk of overdose” (1). The current coronavirus (COVID-19) pandemic

2020 Ontario HIV Treatment Network

37. Effectiveness of mental health electronic medical records

level Hierarchy of Evidence based on a combination of recommendations from the National Health and Medical Research Council (NHMRC), the Oxford Centre for Evidence-based Medicine Levels of Evidence and a publication by Melynyk and Fineout-Overholt (2011). Most of the papers included in our review were graded as low quality, with only two randomised controlled trials identified. Key findings A total of 14 primary research studies focussed on EMRs in mental health settings and eight literature reviews (...) for accuracy of interpretation based on original sources. The terminology used throughout this report is aligned with the Glossary of Usability Terms published by Human Factors International https://humanfactors.com/downloads/Glossary_of_Usability_Terms.pdf Assessment of evidence quality We used The Hierarchy of evidence (Table 3) which includes seven levels based on publications by the National Health and Medical Research Council (NHMRC) (28) the Oxford Centre for Evidence-based Medicine Levels

2020 Sax Institute Evidence Check

38. Intensive Medical Therapy for High-risk Intracranial or Extracranial Arterial Stenosis

; Severe heart failure:New York Heart Association (NYHA) Functional Classification III and IV MRS > 2 before the onset Intravenous or arterial thrombolysis or intravascular therapy after onset Accepting defibrinogen therapy including defibrase and lumbrokinase after onset Creatine Kinase(CK) more than 5 times of the upper limit of normal value after onset Drugs affecting the metabolism of statins such as immune-suppressive drugs, antifungal agents, or fibrates drugs and so on, which were used 14 days (...) Intensive Medical Therapy for High-risk Intracranial or Extracranial Arterial Stenosis Intensive Medical Therapy for High-risk Intracranial or Extracranial Arterial Stenosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2018 Clinical Trials

39. A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users

A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03509285 Recruitment Status : Completed First Posted : April 26, 2018 Last Update Posted : May 2, 2018 Sponsor: SK Life Science, Inc. Information provided

2017 Clinical Trials

40. A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse Full Text available with Trip Pro

A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse An improved synthesis of a haptenic heroin surrogate 1 (6-AmHap) is reported. The intermediate needed for the preparation of 1 was described in the route in the synthesis of 2 (DiAmHap). A scalable procedure was developed to install the C-3 amido group. Using the Boc protectng group in 18 (...) allowed preparation of 1 in an overall yield of 53% from 4 and eliminated the necessity of preparing the diamide 13. Hapten 1 was conjugated to tetanus toxoid and mixed with liposomes containing monophosphoryl lipid A as an adjuvant. The 1 vaccine induced high anti-1 IgG levels that reduced heroin-induced antinociception and locomotive behavioral changes following repeated subcutaneous and intravenous heroin challenges in mice and rats. Vaccinated mice had reduced heroin-induced hyperlocomotion

2017 Journal of medicinal chemistry

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>